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1684-1182/Copyright ª 2014, TaiwanBackground: The tuberculosis (TB) pandemic remains a leading cause of human morbidity and
mortality, despite widespread use of the only licensed anti-TB vaccine, bacille Calmette-
Guerin (BCG). The protective efficacy of BCG in preventing pulmonary TB is highly variable;
therefore, an effective new vaccine is urgently required.
Methods: In the present study, we assessed the ability of novel recombinant BCG vaccine
(rBCG) against Mycobacterium tuberculosis by using modern immunological methods.
Results: Enzyme-linked immunospot assays demonstrated that the rBCG vaccine, which coex-
presses two mycobacterial antigens (Ag85B and CFP10) and human interleukin (IL)-12 (rBCG2)
elicits greater interferon-g (IFN-g) release in the mouse lung and spleen, compared to the
parental BCG. In addition, rBCG2 triggers a Th1-polarized response. Our results also showed
that rBCG2 vaccination significantly limits M. tuberculosis H37Rv multiplication in macro-
phages. The rBCG2 vaccine surprisingly induces significantly higher tumor necrosis factor-a
(TNF-a) production by peripheral blood mononuclear cells that were exposed to a nonmyco-
bacterial stimulus, compared to the parental BCG.titute of Infectious Diseases and Vaccinology, National Health Research Institutes, Number 35, Keyan
0, Taiwan, ROC.
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dx.doi.org/10.1016/j.jmii.2014.11.01Conclusion: In this study, we demonstrated that the novel rBCG2 vaccine may be a promising
candidate vaccine against M. tuberculosis infection.
Copyright ª 2014, Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC. All rights
reserved.Introduction
Tuberculosis (TB) is one of the most prevalent and deadly in-
fectious diseases worldwide. In 2012, 12,845 new cases of TB
were reported in Taiwan with an estimated annual incidence
of 54 cases per 100,000 people (Center for Disease Control,
Taiwan). The current vaccine against Mycobacterium tuber-
culosis is attenuated Mycobacterium bovis bacille Calmette-
Guerin (BCG), which is widely used in preventing TB diseases
such as meningitis, especially during early childhood.1 How-
ever, the efficacy of BCG against adult pulmonary TB remains
controversial.2,3 Taiwan has undertaken comprehensive BCG
vaccination since the 1950s and has witnessed an effective
reduction in TB incidence and mortality rates. However, the
disease has continued to spread. Numerous clinical trials have
investigated the protective ability of BCG and have reported
estimates of 0%e80%.2,3 Thus, a more effective TB vaccine is
urgently required. In previous studies, we found that modern
Beijing lineages are the predominant M. tuberculosis strains
in Taiwan.4,5 For example, as many as 64% of young patients
with TB are infected by a Beijing strain.6 These results suggest
that BCG vaccination may favor the positive selection of
modern Beijing strains.
Efforts to improve the protective efficacy of anti-TB
vaccines include enhancing the current BCG vaccine by
boosting it with new vaccines and developing more effec-
tive vaccines to replace the traditional BCG vaccine. Re-
combinant BCG (rBCG) vaccines now undergoing clinical
assessment employ two strategies to enhance antigenicity
and protective efficacy: (1) overexpression of immunodo-
minant antigens and (2) overexpression of identified anti-
gens that potentially aid in the phagosomal escape of bacilli
to the cytosol. Good examples of such proteins are culture
filtrate protein-10 (CFP10) and 6 kDa early secretory anti-
genic target (ESAT-6).6e8
The BCG vaccines used in most countries are derived from
four major strains: Glaxo strain 1077, Danish strain 1331,
French Pasteur strain 1173 P2, and Tokyo strain 172.9 The
rBCG vaccines in the present studywere created by using BCG
Tokyo strain 172 as the host bacterium and expressing the
cloned Mycobacterium-specific genes Ag85B and CFP10 in
combination with human interleukin (IL)-12 in an attempt to
increase the immune response.10 We previously constructed
two novel rBCG strains: rBCG1(pMVAg85b-CFP10) and
rBCG2(pMVAg85b-CFP10;pVVhIL-12).10Wealsoevaluated the
immune responses elicited by these strains by the charac-
terization of peptide-specific CD4þ and CD8þ Tcell responses
in the lung and spleen. We found that both rBCG vaccines
enhanced Th1 immunity, compared with the traditional BCG
vaccine10; however, the protective effect of the rBCG vac-
cines toward M. tuberculosis was not explicitly determined.
In the present study, we therefore first assessed the ability ofen Y-Y, et al., Recombinant bacill
Mycobacterium tuberculosis, Jou
9the two rBCG strains and BCG to elicit interferon-g (IFNg)-
releasing cells after immunization. In this paper, we
compared the protective ability elicited by immunization
with the parental BCG and with the two rBCG strains.
Materials and methods
Bacterial strains and culture
Mycobacterium bovis BCG (Tokyo 172) and the recombinant
BCG strains (i.e., rBCG1 and rBCG2) and M. tuberculosis
H37Rv were grown on Middlebrook 7H9 medium (Difco Lab-
oratories, Detroit, MI, USA), which was supplemented with
0.5% glycerol, 0.05% Tween-80, and 10% albumin-dextrose-
catalase, or grown on solid 7H11 medium (Difco Labora-
tories), which was supplemented with oleic-acid-albumin-
dextrose-catalase. Oleic-acid-albumin-dextrose-catalase is
added to 7H10 and 7H11 basic media to enhance the growth
of the mycobacteria. When required, the antibiotic kana-
mycin was added at a concentration of 25 mg/mL.
Mice and immunization
Female C57BL/6 and C3H/HeJ mice (6e8 weeks old) used in
this study were purchased from the National Laboratory
Animal Center in Taiwan (Taipei, Taiwan). All animals were
maintained under specific pathogen-free conditions. The
mice (5 mice per group) were immunized subcutaneously
with 1  107 colony-forming units (CFU) of the BCG strain or
rBCG strain in 100 mL of phosphate-buffered saline (PBS).
The control group received 100 mL PBS. The mice were
sacrificed to obtain their sera and splenocytes. All animal
work was approved by the Animal Experimentation Com-
mittee of the National Health Research Institutes (Zhunan,
Taiwan), and performed in accordance with the guidelines
of the committee.
Growth inhibition assay
The assays were performed by coculturing splenocytes from
vaccinated C57BL/6 mice with M. tuberculosis-infected
macrophages. For the assay, murine bone marrow macro-
phages (BMM) were the target cells forM. tuberculosis H37Rv
infection. The BMMfwere prepared by flushing the femurs of
the C57BL/6 female mice with Dulbecco’s modified Eagle’s
medium (DMEM) (Invitrogen, Grand Island, NY, USA), which
was supplemented with 10% heat-inactivated fetal bovine
serum (FBS), 10% L-929a conditioned medium, 1 mM L-gluta-
mine, 1 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic
acid (HEPES) buffer, 1 mM nonessential amino acids, and
1 mM sodium pyruvate [complete DMEM (cDMEM)]. On Days 1e CalmetteeGuerin coexpressing Ag85b, CFP10, and interleukin-12
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24-well plate (Costar, Corning, NY, USA) in cDMEM supple-
mented with 100 units/mL of M-CSF (ProSpec-Tany Tech-
noGene, Ltd., East Brunswick, NJ, USA). Theywere incubated
for 7 days at 37C in 5% carbon dioxide (CO2). The BMMfwere
infected with M. tuberculosis H37Rv at a multiplicity of
infection of 5:1 (i.e., the bacterium:BMMf ratio) for 4 hours at
37C in 5% CO2. The wells were then washed three times with
PBS to eliminate extracellular and nonadhering bacteria.
After the last wash, the PBS was replaced with fresh cDMEM
medium at 37C in 5% CO2. Splenocytes frommice immunized
with theBCG, rBCG1,or rBCG2 vaccineswereused toevaluate
the protective ability of the vaccines against M. tuberculosis
infection in BMMf. At specific times after vaccination
(4 weeks, 8 weeks, and 12 weeks), the spleens from immu-
nized mice were aseptically removed and temporarily placed
in sterile PBS. Based on the description by Parra et al,11 the
spleens were passed through a 100-mm cell strainer (BD Bio-
sciences, Mountain View, CA, USA) to generate a single-cell
suspension and were incubated in ammonium-potassium-
chloride lysis buffer [0.15M ammonium chloride (NH4Cl) and
1mM potassium bicarbonate (KHCO3)] for 4 minutes. To
remove adherent cells, the cells were then resuspended in
cold DMEM and added to culture flasks for 2 hours ofFigure 1. Analysis of antigen-specific interferon-g production. The
assay. Cells from (A, C, E) the spleen and (B, D, and F) the lung were
The cells were stimulated with (A and B) 5 mg/mL Ag85 B and 5 mg/m
protein derivative (PPD). The number of cells secreting interferon
number of dots is significantly increased, compared to the number
BCG Z bacille Calmette-Guerin; PBS Z phosphate-buffered saline;
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dx.doi.org/10.1016/j.jmii.2014.11.019incubation at 37C. Nonadherent splenocytes were harvested
bygentlypipetting the suspensions. Cell viabilitywas assessed
by trypan blue exclusion. Nonadherent splenocytes (5  106
cells) were overlaid on M. tuberculosis-infected BMMf. At
selected time points, the presence of intracellular bacteria in
BMMf was determined by lysing a fraction of the cells with
0.1% saponin and counting the diluted cell lysates by plating.Interferon-g enzyme-linked immunospot assay
As in our previous study, we used the mycobacterial
shared peptides Ag85B241-255aa QDAYNAAGGHNAVFN,
Ag85B261-280aa THSWEYWGAQLNAMKGDLQS, Ag85B1-19aa
FSRPGLPVEYLQVPSMG, CFP1011-25aa LAQEAGNFERISGDL,
and CFP1032-39 VESTAGSL as antigenic stimuli in an IFN-g
enzyme-linked immunospot (ELISPOT) assay.10 The C3H/
HeJ mice were euthanized and their spleens and lungs were
removed aseptically. Cells from the spleens and lungs were
diluted in a culture medium containing an appropriate
stimulus [i.e., 10 mg/mL tuberculin purified protein deriv-
ative (PPD; Statens Serum Institute, Copenhagen, Denmark)
and 5 mg/mL Ag85B/CFP10]. They were then placed in the
wells of the ELISPOT plate at a density of 5  105 cells perimmune response was measured by enzyme-linked immunospot
isolated from mice immunized with PBS, BCG, rBCG1, or rBCG2.
L CFP10, (C and D) PBS, or (E and F) 10 mg/mL tuberculin purified
-g in single-cell suspensions was counted. * Indicates that the
in the group immunized with BCG (p < 0.05). For all figures,
rBCG1 Z recombinant BCG1; rBCG2 Z recombinant BCG2.
e CalmetteeGuerin coexpressing Ag85b, CFP10, and interleukin-12
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Utrecht, Netherlands) was used in accordance with the
manufacturer’s instructions to determine the relative
number of IFN-g-expressing cells in the suspension of single
cells. The spots were visualized and counted. Wells with
fewer than 10 spots were not used for the calculations.
Antibody isotype analysis
For the evaluation of the Th1 and Th2 immune response, sera
from the immunized C3H/HeJ mice were collected and
analyzed by indirect enzyme-linked immunosorbent assay
(ELISA). The ELISA plates were coated overnight at 4C with
recombinant protein Ag85B or CFP10 (DIATHEVA, Fano, Italy)
at a final concentration of 5 mg/mL. The coated plates were
blocked with 200 mL PBS containing 3% bovine serum albumin
at 37C for 1 hour. The plates were washed three times with
PBS containing 0.05% Tween-20. Serumwas added for 2 hours
of incubation, and then washed out, followed by addition of
horseradish peroxidase-conjugated rabbit anti-mouse
immunoglobulin G1 (IgG1) or immunoglobulin G2a (IgG2a)
antibody (Jackson ImmunoResearch Laboratories Inc, West
Grove, PA, USA). The plates were incubated at 37C for 1
hour, washed, and developed with p-phenylenediamine and
hydrogen peroxide substrate. Reactions were stopped by
adding to each well 50 mL of 1N sulfuric acid (H2SO4). The
product was measured on an ELISA plate reader at 492 nm.
Peripheral blood mononuclear cell stimulation
assays
Female C57BL/6micewere immunizedwith BCG or rBCG and
sacrificed after 7 days. The peripheral blood mononuclearFigure 2. Antibody response against Ag85b or CFP10 in mice im
were immunized with PBS, BCG, rBCG1, or rBCG2, respectively, an
their serum for examining (A, B) the antibody response and (C, D) t
(B, D) CFP10.
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dx.doi.org/10.1016/j.jmii.2014.11.019cell (PBMC) fraction was isolated from the blood of the
immunized mice by density centrifugation using a Ficoll-
Paque centrifuge (Pharmacia Biotech, Piscataway, NJ). Cells
were washed three times in saline and resuspended in a
culturemedium [Roswell ParkMemorial Institute (RPMI) 1640
medium; Invitrogen], which was supplemented with 2mM L-
glutamine, 10 mM HEPES and 10% FBS. A total of 2  105
mononuclear cells in a 100-mL volume was added to 96-well
plates containing RPMI or sonicated M. tuberculosis H37Rv
(optical densityZ 1) or Pseudomonas aeruginosa ATCC27853
(optical densityZ 1). After 48 hours, the supernatants were
collected and stored at 20C. The level of tumor necrosis
factor (TNF)-a was assessed by ELISA.Results
Immunization by rBCG elicits IFN-g spot-forming
cells in the spleen and lung
An ELISPOT assay was used to examine the relative numbers
of IFN-g-expressing cells in single-cell suspensions of spleen
and lung tissue from mice immunized with BCG Tokyo 172,
rBCG1, or rBCG2. The antigens PPD and Ag85B/CFP10 were
used to determine the cellular immunity after vaccination
with BCG, rBCG1, or rBCG2. Fig. 1 shows the results at 4
weeks, 8 weeks, and 12 weeks after the mice were immu-
nized with the vaccines. In response to stimulation by the
Ag85B and CFP10 peptides, mice immunized with rBCG1 or
rBCG2 produced high numbers of IFN-g-releasing cells,
compared to mice immunized with PBS (i.e., the control) or
BCG (Fig. 1E and F). Furthermore, the number of IFN-g-
expressing cells in the mice immunized with rBCG1 ormunized with PBS, BCG, rBCG1 or rBCG2. Four groups of mice
d sacrificed after 4 weeks, 8 weeks, and 12 weeks to prepare
he ratio of IgG2a/IgG1. The antigens used were (A, C) Ag85B or
e CalmetteeGuerin coexpressing Ag85b, CFP10, and interleukin-12
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Figure 3. Vaccine inhibition of Mycobacterium tuberculosis
H37Rv growth at days 0, 4, and 7. After (A) 4 weeks, (B) 8 weeks,
and (C) 12 weeks, four groups of mice vaccinated with PBS, BCG,
rBCG1 and rBCG2 were sacrificed. Their spleens were aseptically
removed. Mycobacterium tuberculosis H37Rv-infected macro-
phages were cocultured with splenocytes from mice immunized
with the vaccine. At the specified time points, bacterial uptake
bymurine bonemarrow-derivedmacrophages was determined. *
Indicates that the number of dots is significantly decreased,
compared to the number inmice immunizedwith BCG (p< 0.05).
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There were no significant differences among the cells
stimulated by PBS or PPD (Fig. 1AeD).
Immunization by rBCG promotes the Th1-type
immune response
Fig. 2 illustrates the expression levels of antibody responses
in the sera of mice immunized with BCG, rBCG1, rBCG2, or
PBS (i.e., the control) on using recombinant purified Ag85B
(Fig. 2, left panels) protein or CFP10 (Fig. 2, right panels)
protein as the antigen. Mice immunized with the rBCG1 or
rBCG2 strains produced higher levels of IgG2a antibody
against Ag85B or CFP10, compared to mice immunized with
BCG (Fig. 2A and B). The highest titer of IgG2a antibody
against Ag85B or CFP10 was reached at 8 weeks, and
declined somewhat by 12 weeks (Fig. 2A and B).
Because the Th1 polarized arm of the cellular immune
response is important for protective immunity against
Mycobacterium infection, we also calculated the ratio of
IgG2a to IgG1 to gauge the Th1/Th2 nature of the immune
response in these mice. The IgG2a/IgG1 ratio was highest in
mice immunized with rBCG2 for Ag85B (Fig. 2C) and for
CFP10 (Fig. 2D). The IgG2a/IgG1 ratio in the rBCG2 group
reached its highest point at 8 weeks for CFP10, which was
similar to the IgG2a antibody response (Fig. 2B and D).
However, for Ag85B, the IgG2a/IgG1 ratio in the rBCG2
group reached its highest point at 12 weeks (Fig. 2C). These
results reveal that the ability of the vaccines to induce
Th1/Th2 immunity increased in the following order: PBS,
BCG, rBCG1, and rBCG2. A Th1-polarized response overall
was initiated by both rBCG vaccines.
Vaccination with rBCG limits M. tuberculosis H37Rv
multiplication in macrophages
To further evaluate the protective efficacy of the rBCG1
and rBCG2 vaccines, the ability of splenocytes isolated from
vaccinated mice to inhibit Mycobacterium growth in mac-
rophages was examined. Animals immunized with rBCG1 or
rBCG2 exhibited significantly reduced M. tuberculosis
growth in their macrophages, compared to the PBS or BCG
treatment groups (Fig. 3AeC). The results in Fig. 3B show
that the level of Mycobacterium growth in mice immunized
with rBCG2 for 8 weeks was reduced to approximately 30%
at day 4 and 10% at day 7 in mice immunized with BCG.
After 12 weeks of immunization, the levels of Mycobacte-
rium growth were reduced to approximately 48% and 33% at
days 4 and 7, respectively (Fig. 3C). These results indicate
that rBCG2 vaccination elicited a strong protective immune
response against M. tuberculosis infection.
Vaccination with rBCG promotes nonspecific
protection against P. aeruginosa
To evaluate the innate immunity induced by rBCG vacci-
nation, the ability of PBMCs collected from rBCG-
vaccinated mice to produce TNF-a in response to an unre-
lated pathogen was tested. The PBMCs collected from
rBCG2-vaccinated mice and treated with M. tuberculosis
H37Rv induced 10-fold higher TNF-a production, comparedPlease cite this article in press as: Chen Y-Y, et al., Recombinant bacill
elicits effective protection against Mycobacterium tuberculosis, Jou
dx.doi.org/10.1016/j.jmii.2014.11.019to cells from the BCG group (Table 1). The production of
TNF-a interestingly was also enhanced when the cells were
exposed to a nonmycobacterial stimulus: PBMCs collected
from the rBCG2 group and treated with P. aeruginosa
induced 9-fold to 10-fold higher TNF-a production,
compared with cells from the BCG group (Table 1). It was
surprising that the rBCG2 cells treated with P. aeruginosa
induced 1.4-fold higher TNF-a production, compared to
rBCG2 cells treated with M. tuberculosis H37Rv. These data
demonstrated that rBCG vaccination increased the func-
tional state of circulating mononuclear cells.
Discussion
Bacillus CalmetteeGuerin is widely used as a human vac-
cine against TB. In past decades, numerous laboratoriese CalmetteeGuerin coexpressing Ag85b, CFP10, and interleukin-12
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Table 1 Bacille Calmette-Geurin and recombinant bacille Calmette-Geurin vaccination increases the nonspecific production
of tumor necrosis factor-a by peripheral blood mononuclear cells
PBS BCG rBCG1 rBCG2
No stimulus 0 0 0 0
M. tuberculosis H37Rv 0 16.78  10.66 66.82  25.28 168.09  15.13
P. aeruginosa 0 23.53  4.94 73.18  8.63 237.83  13.61
All data (pg/mL) are presented by the mean  the standard deviation.
BCG Z bacille Calmette-Geurin; M. tuberculosis Z Mycobacterium tuberculosis; P. aeruginosa Z Pseudomonas aeruginosa;
PBS Z phosphate-buffered saline; rBCG Z recombinant bacille Calmette-Geurin.
6 Y.-Y. Chen et al.
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various genetically different BCG sub-strains.12 Bacillus
CalmetteeGuerin has also demonstrated efficacy against
severe forms of TB in children, especially tuberculosis
meningitis; however, it is not effective against pulmonary
TB, which is the predominant form in all age groups.13 Ba-
cillus CalmetteeGuerin is widely used in many countries for
routine vaccination pre-exposure, but it is not used for in-
dividuals with latent TB infection (LTBI).
Various strategies are used to enhance the antituber-
cular immunity of the BCG vaccine. In the early 1990s, BCG
was used as a platform for the heterologous expression of
foreign proteins driven by mycobacterial expression vec-
tors.14 More recent studies indicate that secreted proteins
can be strong candidates for improving the effectiveness of
TB vaccines.15e17 For example, using Ag85B and CFP10 as
the secreted antigens enhances the immune response
of mice against tuberculosis infection.18,19 The expression
of cytokines IL-2, IL-18, and IFN-g by rBCG similarly upre-
gulates the Th-1 immune response in vitro.20,21 Mycobac-
terium tuberculosis and M. bovis secrete Ag85B, and Ag85B
generally behaves as an immunodominant antigen.22 In
guinea pig models, vaccination by rBCG that overexpresses
Ag85B can induce better protection against M. tuberculosis
infection via aerosol challenge.23,24 Culture filtrate protein-
10 is also an immunodominant antigen secreted by M.
tuberculosis, but it is missing in M. bovis BCG.25 In humans,
CD8þ T cells that recognize CFP10 are elicited after M.
tuberculosis infection.26,27
Interferon-g is critical for innate immunity and adaptive
immunity against intracellular infection by pathogens such
as M. tuberculosis. Dendritic cells engulfing mycobacteria
triggers the production of IFN-g and TNF-a, which stimulate
the first antimycobacterial responses that help restrict M.
tuberculosis growth.28 Furthermore, IL-12 produced by
dendritic cells induces a type-1 T cell response.29 In the
present study, the ELISPOT assay demonstrated that rBCG
coexpressing human IL-12, Ag85B, and CFP10 can elicit
strong IFN-g production in the lung and spleen (Fig. 1). This
may help establish a barrier against M. tuberculosis infec-
tion. In addition, rBCG2 can induce a Th-1-polarized immune
response, as demonstrated by the IgG2/IgG1 ratio (Fig. 2).
To verify the protective efficacy, we first isolated sple-
nocytes from vaccine-immunized mice and cocultured them
with macrophages to measure the proliferation rates of M.
tuberculosis in the macrophages. The results demonstrated
that rBCG2 induced strong protection against M. tubercu-
losis H37Rv infection, compared to the protection by the
parental BCG strain. However, it will be necessary to testPlease cite this article in press as: Chen Y-Y, et al., Recombinant bacill
elicits effective protection against Mycobacterium tuberculosis, Jou
dx.doi.org/10.1016/j.jmii.2014.11.019this effect further in a mouse model using aerosol infection.
It has been reported that mice immunized with a rBCG
vaccine exhibit stronger cellular and humoral immune re-
sponses, compared to mice immunized with the parental
BCG vaccine; however, the two groups do not differ with
respect to overall protective efficacy.30 In the near future,
we plan to test the protective efficacy of the rBCG vaccine
by infecting mice with epidemic M. tuberculosis reference
stains such as M. tuberculosis H37Rv via the respiratory
route using a nose-only exposure device.
The effectiveness of BCG vaccination in preventing adult
pulmonary TB is highly variable2,3; however, epidemiolog-
ical studies and scientific reports have suggested that BCG
may provide some special health benefits to vaccines,
including reducing the impact of asthma and possibly ma-
laria.11 Kleinnijenhuis et al indicated that BCG could induce
trained immunity-nonspecific protection from infections
through epigenetic reprogramming.31 In addition, cytokine
production (e.g., IFN-g and TNF-a) by PBMCs isolated from
naı¨ve volunteers after vaccination with BCG increases
significantly when the subjects are exposed to unrelated
pathogens such as Candida albicans and Staphylococcus
aureus.31 Kato et al report that BCG-vaccinated Japanese
flounder is able to mount nonspecific immune responses
against Nocardia seriolae infectiondmost likely through
producing bacteriolytic lysozymes.27 Our results indicated
that when rBCG2 cells were exposed to a nonmycobacterial
stimulus, they were able to induce significantly higher TNF-
a production by PBMCs, compared to the parental BCG
strain (Table 1). To further explore this finding, animal
models incorporating protective assays should be investi-
gated. Our results showed that rBCG2 may be a good vac-
cine candidate against M. tuberculosis infection.Conflicts of interest
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